Celgene International Sàrl, a subsidiary of Celgene Corporation CELG today presented results from a randomized, placebo-controlled
phase II trial in patients with Behçet's disease (BD) at EULAR, the
European Congress of Rheumatology annual meeting in Madrid.
The Company announced statistical significance for the primary endpoint
of the mean number of oral ulcers at week 12 (APR 30 mg BID, 0.5; PBO,
2.1; p<0.0001) evaluating the Company's novel, oral small-molecule
inhibitor of phophodiesterase 4 (PDE4) in patients with Behcet's
disease. The complete response rate (oral ulcer free) at week 12 was
also statistically significant (APR, 71%; PBO, 29%; p<0.0001).
Statistically significant and clinically meaningful responses were
demonstrated across all secondary endpoints, including all
patient-reported outcomes.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in